Global gout therapeutics market is estimated to be an attractive market, which is driven by new drug developments in the pharmaceutical industry and availability of the effective treatment options used as preventive therapies for Gout. Factors such as increasing geriatric base, increasing healthcare expenditure, growing awareness, and rising life expectancy is leading to growth of gout therapeutic market. According to the (Centers for Disease Control and Prevention) CDC, the prevalence of gout was 8.3 million individuals among U.S. adults in 2007–2008 which shows prevalence rate of 3.9%. The demand for gout therapeutics is expected to increase because of the increasing incidences men and women facing gout. The prevalence of gout among men was 6.1 million (5.9%), and the prevalence among women was 2.2 million (2.0%) in 2007-2008. Irregularity in diet, presence of other diseased conditions such as diabetes or kidney diseases and other medications are the factors anticipated to increase the dependence on the market.
Full research report on Global Gout Therapeutics Market Analysis:
The gout therapeutics market is segmented on the basis of products which includes Corticosteroids, NSAIDs (Non-steroidal Anti Inflammatory Drugs) and, Colchicine. The NSAIDs market is one of the dominating markets owing to the increasing preferences for gout treatment while steroids and colchicine and are the treatment options for the patients to whom NSAIDs are contraindicated. Geriatric population is more prone to heart diseases, diabetes and, other life style disorders. This condition worsens their health due to side effects and might also lead to death. Prevention to Gout is also a major concern for which, xzanthine oxidase inhibitors and probenecid are the treatment options as preventive therapy of gout.
Get more information on Global Gout Therapeutics Market or request for TOC of this research report at:
The gout therapeutics market has rising prevalence in North America, Asia Pacific, MEA and Europe. North America is the dominating gout therapeutics market due to increasing geriatric population base with rising life style disorders leading to higher incidences of gout. However, Europe is the next frontier in gout therapeutics market. Asia Pacific is expected to be a lucrative market in upcoming years due to rising economies of India and China leading to improvement in the healthcare infrastructure. According to the CDC, the incidence of gout among black men was almost twice that among white men which shows higher incidences of Gout in MEA.
The major market players of the gout therapeutics market are Savient Pharmaceuticals, Novartis, Teijin Pharma, Regeneron Pharmaceuticals and Takeda. A huge capital of the pharmaceutical companies is involved in the research work for more efficacious and safer treatment alternatives in treatment of gout. Many pharmaceutical companies have either entered into licensing deals or acquired the companies handling potential products for the gout therapeutics market in their portfolio. This is strategic deals are with the objective of introducing new products with better quality, safety and affordability in the gout therapeutics industry.
View more reports of this category by Grand View Research at:
About Grand View Research
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.
Company Name: Grand View Research, Inc.
Contact Person: Sherry James, Corporate Sales Specialist – U.S.A.
Phone: 1-415-349-0058, Toll Free: 1-888-202-9519
Address:28 2nd Street, Suite 3036
City: San Francisco
Country: United States